Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 2
1998 2
1999 3
2001 1
2003 2
2004 3
2007 1
2008 1
2009 1
2010 3
2011 10
2012 6
2013 12
2014 9
2015 13
2016 10
2017 14
2018 17
2019 15
2020 17
2021 14
2022 17
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Rini BI, et al. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H, Gaudino G. Carbone M, et al. Among authors: brugarolas j. Cancer Discov. 2020 Aug;10(8):1103-1120. doi: 10.1158/2159-8290.CD-19-1220. Epub 2020 Jul 20. Cancer Discov. 2020. PMID: 32690542 Free PMC article. Review.
Cell Competition Shapes Metastatic Latency and Relapse.
Kim K, Huang H, Parida PK, He L, Marquez-Palencia M, Reese TC, Kapur P, Brugarolas J, Brekken RA, Malladi S. Kim K, et al. Among authors: brugarolas j. Cancer Discov. 2023 Jan 9;13(1):85-97. doi: 10.1158/2159-8290.CD-22-0236. Cancer Discov. 2023. PMID: 36098678 Free PMC article.
Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J. Chen W, et al. Among authors: brugarolas j. Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5. Nature. 2016. PMID: 27595394 Free PMC article.
An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma.
Zhou J, Simon JM, Liao C, Zhang C, Hu L, Zurlo G, Liu X, Fan C, Hepperla A, Jia L, Tcheuyap VT, Zhong H, Elias R, Ye J, Henne WM, Kapur P, Nijhawan D, Brugarolas J, Zhang Q. Zhou J, et al. Among authors: brugarolas j. Mol Cell. 2022 Aug 18;82(16):3030-3044.e8. doi: 10.1016/j.molcel.2022.06.003. Epub 2022 Jun 27. Mol Cell. 2022. PMID: 35764091 Free PMC article.
A renal cell carcinoma tumorgraft platform to advance precision medicine.
Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. Elias R, et al. Among authors: brugarolas j. Cell Rep. 2021 Nov 23;37(8):110055. doi: 10.1016/j.celrep.2021.110055. Cell Rep. 2021. PMID: 34818533 Free PMC article.
Determinants of renal cell carcinoma invasion and metastatic competence.
Kim K, Zhou Q, Christie A, Stevens C, Ma Y, Onabolu O, Chintalapati S, Mckenzie T, Tcheuyap VT, Woolford L, Zhang H, Singla N, Parida PK, Marquez-Palencia M, Pedrosa I, Margulis V, Sagalowsky A, Xie Z, Wang T, Durinck S, Modrusan Z, Seshagiri S, Kapur P, Brugarolas J, Malladi S. Kim K, et al. Among authors: brugarolas j. Nat Commun. 2021 Oct 4;12(1):5760. doi: 10.1038/s41467-021-25918-4. Nat Commun. 2021. PMID: 34608135 Free PMC article.
165 results